18F-FDG
18F-FDG is a pharmaceutical drug with 68 clinical trials. Currently 24 active trials ongoing. Historical success rate of 86.4%.
Success Metrics
Based on 19 completed trials
Phase Distribution
Phase Distribution
23
Early Stage
11
Mid Stage
4
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
79.2%
19 of 24 finished
20.8%
5 ended early
24
trials recruiting
68
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma
Assessing Granulomatosis With Polyangiitis Activity: 18F-FDG PET/CT vs BVAS v3
Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
Clinical Trials (68)
68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma
Assessing Granulomatosis With Polyangiitis Activity: 18F-FDG PET/CT vs BVAS v3
Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
NeuroFLiPP: Parametric PET of Neuroinflammation in Fatty Liver Disease
Establishment and Clinical Transformation of ADC Drug Efficacy Evaluation System for Breast Cancer Based on Molecular Imaging
Pilot Breast-Dedicated PET Camera With 1 Millimeter Spatial Resolution
Multi-organ Imaging of Microvascular and Metabolic Function
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
5T4 Targeting Nanobody Probe for PET Imaging in Solid Tumors
Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET
Application and Comparison of [68Ga]Ga-FAPI-04 PET, [18F]FDG PET, and Contrast-Enhanced MRI in Predicting Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
EXPLORER Total Body PET/CT Imaging for Myofascial Pain
Single-tracer Multiparametric PET Imaging
CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors
Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Cholesterol Lowering and Residual Risk in Diabetes, Type 1
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 68